<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159578">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01673594</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P-000918</org_study_id>
    <nct_id>NCT01673594</nct_id>
  </id_info>
  <brief_title>Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to a) assess the efficacy of naltrexone in preventing
      stimulant-induced euphoria in adults with ADHD, b) assess whether naltrexone will interfere
      with the clinical efficacy of stimulants in treating adults with ADHD, c) assess whether
      naltrexone will interfere with the effects of stimulants on neurotransmitter activity. We
      predict that naltrexone will successfully prevent stimulant-induced euphoria without
      interfering with the ability of stimulants to effectively treat ADHD in adults. This study
      will be an 8 -week trial with young adults (18-24) with ADHD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy (positive, or 'liking' response to stimulant medication) will be assessed by the change in the Drug Rating Questionnaire - Subject (DRQ-S).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ADHD</condition>
  <condition>Stimulant-Induced Euphoria</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Naltrexone + SODAS MPH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2: Placebo + SODAS MPH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SODAS MPH</intervention_name>
    <description>Adults with ADHD will receive open-label SODAS MPH</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Ritalin LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Subjects randomized to the &quot;active&quot; double-blind group will receive Naltrexone HCl</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Naltrexone HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          1. Male or female adults ages 18-30 years.

          2. A diagnosis of ADHD, per clinical evaluation

          3. At least a minimal likeability response (&gt; 5)  on the DRQ-S  after an initial test
             dose of 60mg of IR MPH.

          4. Baseline ADHD severity of &gt; 24 on the AISRS.

          5. Able to participate in blood draws and to swallow pills.

          6. Able to understand the nature of the study, to sign an informed consent document and
             to be considered reliable reporters

        Exclusion

          1. Any current (last month), non-ADHD Axis I psychiatric conditions

          2. Significant current anxiety or depression based on Ham-D &gt; 16, BDI &gt; 19, or Ham-A &gt;
             21

          3. Any clinically significant chronic medical condition, including cardiovascular
             disease or hypertension

          4. Clinically significant abnormal baseline laboratory values

          5. I.Q. &lt; 80

          6. Organic brain disorders

          7. Seizures or tics

          8. Pregnant or nursing females

          9. Clinically unstable psychiatric conditions (i.e. suicidal behaviors, psychosis)

         10. Current or recent (within the past year) substance abuse/dependence

         11. Current use of other psychotropic medication(s)

         12. Current or prior adequate treatment with MPH

         13. Known hypersensitivity to methylphenidate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Spencer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Grossman, B.S.</last_name>
    <phone>617-643-1432</phone>
    <email>rgrossman1@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariana Koster</last_name>
      <phone>617-724-2858</phone>
      <email>AKOSTER@PARTNERS.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>June 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thomas J. Spencer, MD</investigator_full_name>
    <investigator_title>Associate Chief, Clinical and Research Program,  Pediatric Psychopharmacology</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>SODAS MPH</keyword>
  <keyword>Stimulant-Induced Euphoria</keyword>
  <keyword>Substance Abuse</keyword>
  <keyword>Adults</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
